Skip to main content

Table 2 Specific clinical characteristics and pharmacological history of the SLE patients

From: First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

  SLE (n = 66)
Baseline laboratory findings
 Total leukocytes (N cells/mm3, median (IQR)) 7.0 (4.5–9.1)
 Total lymphocytes (N cells/mm3, median (IQR)) 0.9 (0.5–1.4)
 CD19 positive cells (n = 37) (N cells/mm3/percentage median (IQR)) 0.05 (0.03–0.12)/7.0 (4.0–13.0)
 Anti-dsDNA positivity, (n, %) 44 (66.7)
 Low complement levels (n = 61), (n, %) 35 (57.4)
Primary indication for RTX
 Lupus nephritis, n (%) 42 (63.6)
 Neurolupus, n (%) 7 (10.6)
 Lupus related arthritis, n (%) 7 (10.6)
 Mucocutaneous manifestations, n (%) 2 (3.0)
 Haematological manifestations, n (%) 5 (7.6)
 Other manifestationsa, n (%) 3 (4.5)
Ongoing treatment at RTX initiation
 Oral Prednisolone, n (%) 61 (92.4),
 Daily dose, mg (median (IQR)) 12.5 (12.5–20.0)
 Antimalarials, n (%) 27 (40.9)
 Azathioprine, n (%) 6 (9.1)
 Mycophenolate, n (%) 9 (13.6)
 Methotrexate, n (%) 3 (4.5)
Previous treatments
 Cyclophosphamide, n (%) 40 (60.6)
 Cumulative dose (median (IQR)) 6075 (3150–9275)
 Azathioprine, n (%) 44 (66.7)
 Mycophenolate, n (%) 32 (48.5)
 Methotrexate, n (%) 17 (25.8)
 Cyclosporine A, n (%) 11 (16.7)
  1. IQR Interquartile range, n Number, CD19 Cluster of differentiation 19, anti-dsDNA Anti-double strand-DNA antibodies
  2. aOther manifestation: one fatigue and systemic inflammation, one lung fibrosis, one peripheral polyneuropathy